 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C25H40FNAO6S |
| Exact Mass | 510.242 |
| CAS # | 2553218-46-3 |
| Related CAS # | BSH-IN-1;2553217-91-5 |
| PubChem CID | 145713840 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 34 |
| Complexity | 849 |
| Defined Atom Stereocenter Count | 10 |
| SMILES | C[C@H](CCC(=O)CF)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)OS(=O)(=O)[O-])C)O)C.[Na+] |
| InChi Key | GVCGSXGVFOXFAT-CTSSCMOWSA-M |
| InChi Code | InChI=1S/C25H41FO6S.Na/c1-15(4-5-17(27)14-26)19-6-7-20-23-21(9-11-25(19,20)3)24(2)10-8-18(32-33(29,30)31)12-16(24)13-22(23)28;/h15-16,18-23,28H,4-14H2,1-3H3,(H,29,30,31);/q;+1/p-1/t15-,16+,18-,19-,20+,21+,22-,23+,24+,25-;/m1./s1 |
| Chemical Name | sodium;[(3R,5R,7R,8R,9S,10S,13R,14S,17R)-17-[(2R)-6-fluoro-5-oxohexan-2-yl]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] sulfate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Bile salt hydrolase (BSH)[1] |
| ln Vitro | The epithelial barrier integrity of Caco-2 cells was not affected by the BSH Inhibitor Gut Restricted-7 (GR-7) (60 μM), suggesting that this molecule is comparatively benign. Additionally, microbial biomass is unaffected by gut restricted-7 [1]. |
| ln Vivo | For one day, C57BL/6 mice were given either a powdered food that contained 0.09% of Gut Restricted-7 (GR-7) (w/w) or just the powdered diet. Eight hours after a food shift, gut restricted-7 dramatically reduced BSH activity in the excrement of mice treated with inhibitors. Cecal contents contained 20 pmol/mg wet weight (~20 μM) of gut restricted-7 [1]. |
| References | [1]. Adhikari AA, et al. Development of a covalent inhibitor of gut bacterial bile salt hydrolases. Nat Chem Biol. 2020 Mar;16(3):318-326. |
Solubility Data
| Solubility (In Vitro) |
DMSO: 250 mg/mL (489.59 mM) H2O: ≥ 100 mg/mL (195.84 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.19 mg/mL (4.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.9 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |